Castle Biosciences to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

Rhea-AI Summary

Castle Biosciences, Inc. (Nasdaq: CSTL) will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on Thursday, Nov. 18, 2021, at 9:30 a.m. Eastern time. CEO Derek Maetzold and CFO Frank Stokes will share insights about the company’s innovative diagnostics aimed at improving patient outcomes. Live audio webcasts will be available on the company’s website, with replays accessible for two weeks post-event. Castle specializes in personalized genomic information for better treatment decisions in cancers like melanoma.

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company applying innovative diagnostics to inform disease management decisions and improve patient outcomes, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on Thursday, Nov. 18, 2021, at 9:30 a.m. Eastern time.

Live audio webcasts of the company’s presentations will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx. Replays of the webcasts will be available for two weeks following the conclusion of the live broadcasts.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a commercial-stage diagnostics company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx®-Melanoma, DecisionDx® -CMSeq), cutaneous squamous cell carcinoma (DecisionDx®-SCC), suspicious pigmented lesions (myPath® Melanoma and DecisionDx® DiffDx™-Melanoma) and uveal melanoma (DecisionDx®-UM, DecisionDx®-PRAME and DecisionDx®-UMSeq). For more information about Castle’s gene expression profile tests, visit www.CastleTestInfo.com.

Castle also has active research and development programs for tests in other dermatologic diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate to severe psoriasis, atopic dermatitis and related conditions. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix.

For more information, visit www.CastleBiosciences.com.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005205/en/

Investor Contact:

Camilla Zuckero

832-835-5158

czuckero@castlebiosciences.com

Media Contact:

Allison Marshall

amarshall@castlebiosciences.com

Source: Castle Biosciences, Inc.

FAQ

What is the date and time of Castle Biosciences' presentation at the Canaccord Genuity Forum?

Castle Biosciences' presentation is scheduled for Thursday, Nov. 18, 2021, at 9:30 a.m. Eastern time.

Who will represent Castle Biosciences at the Canaccord Genuity Forum?

Derek Maetzold, CEO, and Frank Stokes, CFO, will represent Castle Biosciences at the event.

Where can I access the webcast of Castle Biosciences' presentation?

The webcast can be accessed through Castle Biosciences' official website.

What focus does Castle Biosciences have in diagnostics?

Castle Biosciences focuses on providing personalized genomic information to inform treatment decisions for cancer patients.

What types of tests does Castle Biosciences offer?

Castle offers tests for cutaneous melanoma, squamous cell carcinoma, and suspicious pigmented lesions, among others.